On November 21, 2022, BrightGene Bio-Medical Technology Co., Ltd. closed the transaction. The company amended the terms of the transaction. The company issued 12,464,966 new shares at a price of CNY 18.18 per share for gross proceeds of CNY 226,613,081.88 in the transaction.

The transaction included participation from Horizon Asset Management Co. Ltd. for CNY 168,999,989.22, Suzhou Suxin Equity Investment Partnership (Limited Partnership) for CNY 29,999,999.70, Shanghai Leitu Asset Management Co., Ltd. for CNY 17,613,093.06, Changsha Commercial Logistics Co., Ltd. for CNY 9,999,999.90. After deducting the issuance expenses of CNY 6,798,784.56, the actual net proceeds raised CNY 219,814,297.32, including newly added registered capital of CNY 12,464,966.00 and capital reserve of CNY 207,349,331.32.